Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.

Schulz, Felicitas; Nachtkamp, Kathrin; Kasprzak, Annika; Gattermann, Norbert; Haas, Rainer; Germing, Ulrich

Schulz, Felicitas; Nachtkamp, Kathrin; Kasprzak, Annika; Gattermann, Norbert; Haas, Rainer; Germing, Ulrich.

Affiliation

Schulz F; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
Nachtkamp K; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
Kasprzak A; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
Gattermann N; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
Haas R; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
Germing U; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.

Expert Rev Hematol ; 14(6): 509-516, 2021 06.

Article in En | MEDLINE | ID: mdl-34161752

Subject(s)

Myelodysplastic Syndromes; Quality of Life; Activin Receptors, Type II/therapeutic use; Aged; Humans; Immunoglobulin Fc Fragments/therapeutic use; Myelodysplastic Syndromes/diagnosis; Myelodysplastic Syndromes/drug therapy; Recombinant Fusion Proteins

Key words

Erythropoiesis stimulating agents; luspatercept; mds; myelodysplastic syndromes; tgf-beta

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Myelodysplastic Syndromes Type of study: Diagnostic_studies / Prognostic_studies Aspects: Patient_preference Limits: Aged / Humans Language: En Journal: Expert Rev Hematol Journal subject: HEMATOLOGIA Year: 2021 Document type: Article Affiliation country: Germany Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google